BOSENTAN: payments to doctors
Payments that named BOSENTAN as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $32K
- Providers
- 240
- Transactions
- 367
- Average per transaction
- $87
The per-transaction average — $87 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 240 providers the average total is $133, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $29,195 | 91.6% |
| Johnson & Johnson | $1,364 | 4.3% |
| Hikma Pharmaceuticals USA | $990 | 3.1% |
| Janssen Research & Development, LLC | $311 | 1.0% |